This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.

Start Date01 Apr 2025

Sponsor / Collaborator

VA Office of Research and Development

NCT05339256

/ Not yet recruitingPhase 2IIT

A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine Vs In-Person Care As Usual in the Treatment of Opioid Use Disorder

This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).

Start Date01 Mar 2025

Sponsor / Collaborator

The New York State Psychiatric Institute

[+1]

NCT04454411

/ Not yet recruitingPhase 2IIT

Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder

This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key cognition functions. The study will use previously validated cognitive probes, functional Magnetic Resonance Imaging (fMRI), and novel extended-release injectable preparations of opioid partial agonist buprenorphine and antagonist naltrexone, in OUD patients to explain the individual heterogeneity of OUD treatment response.

Start Date01 Feb 2025

Sponsor / Collaborator

University of Pennsylvania

100 Clinical Results associated with Buprenorphine

100 Translational Medicine associated with Buprenorphine

100 Patents (Medical) associated with Buprenorphine

9,511

Literatures (Medical) associated with Buprenorphine

01 Feb 2025·BRAIN BEHAVIOR AND IMMUNITY

Peripartum buprenorphine and oxycodone exposure impair maternal behavior and increase neuroinflammation in new mother rats

Article

Author: Singleton, Jordyn J ; Webb, Aliyah I ; Dye, Courtney N ; Ringland, Amanda ; Lenz, Kathryn M ; Leuner, Benedetta ; Fankhauser, Madison P ; Kalathil, Aravind

7 % of pregnant people use opioids. Opioid use during pregnancy can negatively impact maternal and offspring health. Medications for opioid use disorder (MOUD), commonly buprenorphine, are the recommended treatment for opioid use disorder during pregnancy to prevent cycles of withdrawal and relapse. In addition to effects on opioid receptors, opioids have strong binding affinity to toll-like receptor (TLR) 4, an immune cell receptor, and thereby impact neuroinflammatory signaling. We have previously shown that neuroimmune alterations are important for the display of maternal behavior. Here, we used a rodent model to assess the impact of chronic peripartum opioid exposure or MOUD on maternal caregiving and neuroinflammation in the postpartum brain. Female rats were exposed to vehicle (VEH), buprenorphine (BUP) to model MOUD, or oxycodone (OXY), to model peripartum drug use, before, during, and after pregnancy. Opioid exposure reduced gestation length and maternal weight gain. Postpartum maternal caretaking behaviors, including pup retrieval, huddling and nursing, and pup-directed sniffing and licking, were reduced in opioid-exposed mothers. Following behavioral testing, tissue was collected from brain regions important for maternal caretaking, including the prefrontal cortex (PFC), nucleus accumbens (NAc), preoptic area (POA), amygdala (AMY), and periaqueductal grey (PAG). Immunofluorescent labeling showed that BUP increased astrocyte labeling, while OXY increased microglia labeling in the PAG, but not other regions. Gene expression analysis also showed regional and treatment differences in immune transcripts. BUP and OXY increased TLR4 in the PFC. BUP increased TNF in the NAc but decreased IL1β in the POA. OXY increased CD68 in the POA, and IL1β, TNF, and TLR4 in the PAG. Together, these results provide novel evidence of peripartum neuroimmune alterations following chronic opioid exposure that could be mediating maternal care deficits. This work provides a foundation to explore the extent to which modulation of neuroimmune activation may be a potential intervention for caregiving deficits in mothers exposed to opioids during pregnancy.

01 Feb 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Buprenorphine initiation and rates of associated precipitated withdrawal in patients with fentanyl use in an urban emergency department

Article

Author: Geier, Curtis ; Ly, Janice ; Checkley, Laura ; LeSaint, Kathy T

BACKGROUND:

Fentanyl use has been linked with an increasing number of opioid-related deaths. The emergency department (ED) is a critical contact point for patients with opioid use disorder (OUD) to access basic healthcare. Little information is known about buprenorphine precipitated opioid withdrawal (BPOW). This study sought to examine the rates of BPOW in patients who used fentanyl and received buprenorphine in the ED.

METHODS:

A retrospective cohort study was conducted in a single emergency department in an urban city and included patients who reported use of fentanyl and who received buprenorphine for opioid withdrawal. The primary outcome was occurrence of BPOW, in which we assessed for interrater reliability between data abstractors. Data extraction included patients' demographic characteristics, date of service, length of stay, Clinical Opiate Withdrawal Scale (COWS) score assessments, dosages of administered buprenorphine, occurrence of BPOW, and ED disposition.

RESULTS:

Over the course of 28 months, buprenorphine was administered 113 patients (12.5 %) who reported using fentanyl prior to their ED presentation. The majority of patients identified as White (49 %), and most patients presented with a chief complaint other than specific opioid related concerns. Fifty-one patients (45 %) had an initial COWS score documented, with a median score of 11. Three patients (2.6 %) had BPOW, two of whom required intensive care unit (ICU) admission.

CONCLUSIONS:

We demonstrate that the prevalence of BPOW is low in a cohort of patients who use fentanyl. When precipitated withdrawal does occur, however, it can be severe and require intensive treatment, ICU admission, and prolonged hospital stay.

01 Feb 2025·Journal of substance use and addiction treatment

An initial randomized controlled trial of a Combined Medication and Behavioral Activation Treatment (CoMBAT) for people with opioid use disorder

Article

Author: Mimiaga, Matthew J ; Hughes, Landon D ; Nelson, Kimberly M ; Perry, Nicholas S ; Bailey, Amelia ; Biello, Katie B ; Hughto, Jaclyn M W ; Pantalone, David W

INTRODUCTION:

Opioid use disorder is a chronic, relapsing disease and a major source of morbidity and mortality in the U.S. Medications for opioid use disorder (MOUD) have been shown to reduce opioid use; however, MOUD maintenance is often suboptimal. Depression is a well-documented risk factor for MOUD treatment disengagement; thus, behavioral interventions to address depression and support ongoing MOUD use in community settings are warranted.

METHODS:

We evaluated the feasibility, acceptability, and preliminary efficacy of the CoMBAT (Combined Medication and Behavioral Activation Treatment) intervention via a pilot randomized controlled trial. We hypothesized that the CoMBAT intervention, which uses behavioral activation, motivational interviewing, and problem-solving techniques, would be feasible and acceptable to participants and decrease depression, increase goal-directed activity, improve MOUD care engagement, and reduce opioid use among adults with depressive symptoms who had a missed dose or clinical MOUD visit in the past 30 days. We enrolled 32 participants prescribed methadone or buprenorphine in the community; each received 2 health navigation and substance use counseling sessions (HN_SUC) before being randomized into (a) the 8-session CoMBAT intervention + HN_SUC + treatment as usual or (b) HN_SUC + treatment as usual only. The primary outcomes were intervention feasibility and acceptability. Preliminary efficacy measures included self-reported past-30-day MOUD doses and clinical visits, depressive symptoms, behavioral activation; and opioid-positive urinalysis; each assessed at baseline and 3- and 6-month follow-up visits.

RESULTS:

The intervention was feasible (88 % of intervention sessions completed; 100 % retention at 6 months) and acceptable (86 % of intervention participants were satisfied/very satisfied with the intervention at 3-months; and intervention participants had a high level of alliance with their counselor at the mid-point: mean = 5.7 out of 7 [SD = 1.3] and end of their treatment: mean = 5.5 out of 7 [SD = 1.1]. At 6-months, intervention participants reported fewer missed MOUD doses and visits, less depressive symptoms, greater behavioral activation scores, and a lower percentage of opioid-positive toxicology screens relative to the control condition.

CONCLUSION:

Findings provide evidence of intervention feasibility and acceptability and demonstrate initial efficacy for ongoing MOUD care engagement, depressive symptom reduction, increased behavioral activity, and reduced opioid use. Future intervention testing in a fully-powered efficacy trial is warranted.

News (Medical) associated with Buprenorphine

19 Nov 2024

·www.indivior.com

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly. Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly. Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder. Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder. Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal injection site, were also presented at CSAM. Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal injection site, were also presented at CSAM. SUBLOCADE has received Priority Review designation from the U.S. Food and Drug Administration (FDA) to expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose as well as inclusion of alternative injection sites. SUBLOCADE has received Priority Review designation from the U.S. Food and Drug Administration (FDA) to expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose as well as inclusion of alternative injection sites. RICHMOND, Va., Nov. 19, 2024 -- Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE® (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inject opioids or use fentanyl without increasing the risk of precipitated opioid withdrawal (POW) symptoms. The data were presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference in Hamilton, Ontario, Canada. “These findings underscore the potential for rapid initiation to transform opioid use disorder treatment,” said Dr. Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “Rapid initiation may improve patient retention and meet the immediate needs brought on by synthetic opioids in real-world settings, offering a practicable path to stabilization and long-lasting, meaningful recovery.” Conducted across multiple sites, this non-inferiority study included 729 participants (mean age 42, average opioid use of 15 years), stratified by fentanyl presence in urine screens, with an observed 78% fentanyl-positive rate. Patients randomized to RI received a single dose of 4 mg transmucosal buprenorphine (TM-BUP), followed by a SUBLOCADE injection within 1 hour. The primary endpoint was treatment retention at injection 2, administered 1 week after injection 1 comparing it to the current standard regimen of 28 days. Those in the SI group received daily TM-BUP doses over ≥7 days before injection, and if non-inferiority was met, superiority was assessed. Among the participants, RI was superior to SI in retention rates at injection 2, with a 12% improvement overall and 15% in the fentanyl-positive group. The shorter dose interval between BUP-XR injection 1 and 2 was designed to achieve and maintain buprenorphine plasma concentrations more quickly at target levels of 2 ng/mL. The overall Treatment Emergent Adverse Events (TEAE) profile up to Injection 2 was comparable for RI and SI. There were no unexpected safety findings. Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks were also presented at CSAM (NCT04995029). SUBLOCADE has received Priority Review designation granted by the U.S. Food and Drug Administration (FDA) for a labeling supplement, which would expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose and also expands from the current subcutaneous abdominal injection site for induction and maintenance to alternative injection sites including the thigh, upper arm, and buttocks. With a Prescription Drug User Fee Act (PDUFA) action date set for February 7, 2025, this Prior Approval Supplement (PAS) submission, if approved, could allow healthcare providers a flexible approach to initiate treatment rapidly, supporting better retention outcomes for OUD patients, particularly those testing positive for fentanyl. A Priority Review designation means that the FDA's goal is to take action on an application within 6 months (compared to 10 months under standard review). If approved, this label change could translate into significant improvements in OUD treatment with SUBLOCADE. +++ This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the Canadian Society of Addiction Medicine. +++ About SUBLOCADE® SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously. Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS SUBLOCADE should not be administered to patients who have been shown to be hypersensitive to buprenorphine or any component of Indivior's proprietary buprenorphine gel depot delivery system. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Opioids can cause sleep-related breathing disorders e.g., central sleep apnea (CSA), sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. Consider decreasing the opioid using best practices for opioid taper if CSA occurs. Strongly consider prescribing naloxone at SUBLOCADE initiation or renewal because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. Educate patients and caregivers on how to recognize respiratory depression and how to treat with naloxone if prescribed. Risk of Serious Injection Site Reactions: The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration, and necrosis. The likelihood of serious injection site reactions may increase with inadvertent intramuscular or intradermal administration. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off the opioid. Risk of Opioid Withdrawal With Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patient is clinically stable on transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com. About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences.1 OUD may affect the parts of the brain that are necessary for life-sustaining functions.1,2 Important Cautionary Note Regarding Forward-Looking Statements This press release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: Indivior PLC’s expectations regarding the timing of approval for the PAS for rapid induction and injection sites, and the potential impact on OUD treatments and Sublocade from such; and other statements containing the words "believe," "anticipate," "plan," "expect," "expectations," "intend," "estimate," "forecast," “strategy,” “target,” “guidance,” “outlook,” “potential,” "project," "priority," "may," "will," "should," "would," "could," "can," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including: failure or delay in obtaining approval of the PAS and the acceptance by HCPs and their patients of the perceived benefits of such PAS changes. For information about some of the risks and important factors that could affect our future results and financial condition, see "Risk Factors" in Indivior's Annual Report on Form 20-F for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission. We have based the forward-looking statements in this press release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this press release apply only at the date of this press release and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, future developments, or otherwise. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. Media Contacts: US Media: Cassie France-Kelly VP, Communications Indivior PLC Tel: +1(804) 724-0327 References  National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder, Mancher, M., & Leshner, A. I. (Eds.). (2019). Medications for Opioid Use Disorder Save Lives. National Academies Press (US). Accessed October 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK538936/pdf/Bookshelf_NBK538936.pdf NIDA. 2022, March 22. Drugs and the Brain. Accessed October 30,2023, from https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drugs-brain

Clinical ResultPriority ReviewPhase 3

07 Nov 2024

·www.camurus.com

Camurus’ Interim Report Third Quarter 2024

“Solid third quarter and raised full-year outlook” Summary third quarter 2024 July - September January - September Significant events after the period Financial summary third quarter 2024 Excluding one-time milestones related to the Brixadi approval by the FDA in the US in 2023 At constant exchange rate Fredrik Tiberg, President and CEO: “Camurus has had another good quarter with positive financial development and excellent performance across our businesses. Sales of Buvidal and Brixadi continued to grow, resulting in our best result to date, excluding one-time revenues. Our pipeline progressed well with positive Phase 3 results from the ACROINNOVA 2 study, confirming the long-term safety profile and efficacy of CAM2029 in patients with acromegaly. In parallel, our clinical studies of CAM2029 for the treatment of neuroendocrine tumors and polycystic liver disease advanced. In the US, the FDA continued its review of our new drug application for CAM2029 in acromegaly. After the quarter, a Complete Response Letter was received from the Agency, solely relating to a cGMP-inspection at a third-party manufacturing site and pending issuance of an inspection classification.” Audiocast Financial analysts and media are invited to attend a telephone conference and presentation of the results today at 2.00 pm (CET). The conference call can also be followed by a link on www.camurus.com or via external link: https://financialhearings.com/event/48851 For more information: Fredrik Tiberg, President and CEO Tel. +46 (0)46 286 46 92 fredrik.tiberg@camurus.com Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 ir@camurus.com About Camurus Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disease, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com. This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, at 07.00 am CET on 7 November, 2024.

Financial StatementClinical ResultDrug ApprovalPhase 3

31 Oct 2024

·www.businesswire.com

Anthem Blue Cross and Blue Shield Foundation Awards $600,000 Grant to Care for the Homeless

NEW YORK--( BUSINESS WIRE )--Anthem Blue Cross and Blue Shield Foundation today announced a $600,000 grant to Care For the Homeless (CFH) to expand its "Bronx Health Reach Initiative," a program addressing mental health and substance use disorders among the South Bronx homeless population. The Bronx Health Reach Initiative is a vital street-based outreach program designed to combat mental health and substance use crises, focusing on Medication-Assisted Treatment (MAT) for opioid addiction. In 2023, CFH provided trauma-informed services to over 11,000 homeless individuals in New York City, a 15% increase from the previous year. “The mental health and substance use disorder crisis affecting the homeless community deserves urgent and sustained support. This grant will enable Care For the Homeless to expand critical services and ensure access to much-needed treatment for vulnerable populations,” said Dr. Mark Levy, President and CEO of Anthem Blue Cross and Blue Shield. “At Anthem, we believe in addressing social determinants of health in a way that drives meaningful and measurable outcomes in the communities we serve.” Care For the Homeless President & CEO George Nashak added, “Recovery begins with accessible, compassionate care. This grant from Anthem allows us to deepen our impact in the South Bronx, particularly in reaching individuals who are battling both homelessness and substance use disorders. Expanding our immediate street-based initiation of Medication-Assisted Treatment (MAT) to address the opioid crisis allows us to provide timely, life-saving treatment to those who need it most.” The two-year grant will enhance outreach, staffing, and treatment resources, strengthening CFH's partnerships and increasing community engagement. With the opioid crisis continuing to impact the Bronx, this expansion is crucial for providing sustainable recovery opportunities. In addition to expanding access to care, the Bronx Health Reach Initiative will implement a comprehensive strategy to address the critical gaps in mental health and substance use disorder treatment within the South Bronx's homeless population. A key focus of the program is the immediate street-based initiation of Medication-Assisted Treatment (MAT), particularly with Buprenorphine, a proven treatment for opioid addiction. By engaging individuals directly where they are, the program aims to remove barriers to treatment and foster long-term recovery. The initiative will utilize a mixed-methods approach, conducting pre- and post-assessments to track progress and impact. Key performance metrics will include treatment engagement, housing stability, and community support. Regular checkpoints, including participant surveys and clinical data reviews, will ensure ongoing program evaluation, allowing for real-time adjustments to enhance effectiveness. CFH projects that over two years, the program will reach 3,300 people, with more than 1,250 individuals expected to participate in the full range of services, including mental health counseling, substance use treatment, and housing support. By prioritizing timely intervention and fostering strong community partnerships, the program aims to improve treatment adherence and access to care for participants by 40% while improving long-term housing stability and quality of life outcomes. The ultimate goal is to create a sustainable recovery model that addresses the immediate and ongoing needs of the South Bronx's most vulnerable populations. About Care For the Homeless Care For the Homeless (CFH) is a 501(c)(3) non-profit and is committed to providing individuals experiencing homelessness with high-quality medical, mental, and behavioral health care services. In addition, CFH actively advocates for policies to prevent and end homelessness. CFH also currently operates six housing facilities including four transitional shelters for adult men and women and two Safe Havens for street homeless men, all of which have on-site health care services, as well as twenty-three health care delivery sites across all five New York City boroughs. For more information, visit www.careforthehomeless.org . About Anthem Blue Cross and Blue Shield Foundation The Anthem Blue Cross and Blue Shield Foundation, an independent licensee of the Blue Cross and Blue Shield Association, is a philanthropic arm of the Elevance Health Foundation. The Foundation works to address health equity by focusing on improving the health of the socially vulnerable through strategic partnerships and programs in our communities with an emphasis on maternal child health; mental health; and food as medicine. Additionally, the Foundation also responds to disasters when our communities need us the most. The Foundation coordinates the company’s year-round Dollars for Dollars program which provides a 100 percent match of associates’ donations, as well as its Volunteer Time Off and Dollars for Doers community service programs. ®ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbol are registered marks of the Blue Cross and Blue Shield Association. To learn more about the Anthem Blue Cross and Blue Shield Foundation and the Elevance Health Foundation, please visit https://www.elevancehealth.foundation/ and its blog at www.medium.com/elevancehealthfoundation .

100 Deals associated with Buprenorphine

External Link

KEGG	Wiki	ATC	Drug Bank
D07132	Buprenorphine	N07BC01	DB00921

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Opioid-Related Disorders	US	Braeburn, Inc.	23 May 2023
Opium Dependence	EU	Camurus AB	20 Nov 2018
Opium Dependence	IS	Camurus AB	20 Nov 2018
Opium Dependence	LI	Camurus AB	20 Nov 2018
Opium Dependence	NO	Camurus AB	20 Nov 2018
Opioid abuse	US	Indivior, Inc.	30 Nov 2017
Pain	US	Purdue Pharma LP	13 Oct 2017
Chronic Pain	US	Purdue Pharma LP	30 Jun 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cancer Pain	Phase 3	CN	LTS LOHMANN Therapie-Systeme AG	10 Jun 2019
Cancer Pain	Phase 3	CN	Grünenthal GmbH	10 Jun 2019
Cancer Pain	Phase 3	CN	Beijing Mengdi Pharmaceutical Co. Ltd.	10 Jun 2019
Analgesia	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Pain, Postoperative	Phase 3	-	Purdue Pharma LP	01 Nov 2011
opioid dependence methadone	Phase 3	US	Titan Pharmaceuticals, Inc.	01 Sep 2008
Osteoarthritis, Knee	Phase 3	US	Purdue Pharma LP	01 Sep 2007
Osteoarthritis	Phase 3	US	Purdue Pharma LP	01 Apr 2004
Low Back Pain	Phase 3	US	Purdue Pharma LP	01 Feb 2004
Irritable Bowel Syndrome	Phase 2	US	OrphoMed, Inc.Startup	22 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03605342 (CTgov)	Phase 2	Opioid abuse \| Stress Disorders, Post-Traumatic	38	Cognitive Processing Therapy (CPT)+Buprenorphine (Buprenorphine + CPT-C)	cldzyzbqez(gevvfdrdun) = zvyppttcci azuchxcxwe (qujyauxsch, ejlaajxfhn - ryeajzrnfk) View more	-	19 Aug 2024
				Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC)	cldzyzbqez(gevvfdrdun) = wjshrttclc azuchxcxwe (qujyauxsch, lsndmxnqtu - kzjqbmvcps) View more
NCT04225598 (Pubmed)	Phase 2	-	100	Extended-Release Buprenorphine (CAM2038)	bvlkvficua(kmbvpntvjd) = xxkhccfkde sdzpiarugl (ryehiretbm ) View more	Positive	08 Jul 2024
NCT02651584 (PRNewswire) Manual	Phase 3	Opioid-Related Disorders	123	BRIXADI (fentanyl-positive)	uxsrywxiah(bmrgcquajb) = zysvbchusz deruytfctj (snwjynefcq ) View more	Positive	25 Jun 2024
				buprenorphine + naloxone (fentanyl-positive)	uxsrywxiah(bmrgcquajb) = dbxfgdjfgs deruytfctj (snwjynefcq ) View more
NCT02651584 (Pubmed)	Phase 3	fentanyl-positive \| norfentanyl	428	Subcutaneous Buprenorphine	cltjnjeduy(ovfykwhruq) = bkvfipxnmh bzozclzdlr (whcpaehvum )	Positive	03 Jun 2024
				Sublingual Buprenorphine-Naloxone	cltjnjeduy(ovfykwhruq) = exszrhnkzg bzozclzdlr (whcpaehvum )
NCT04254081 (ABCD&E, CTgov)	Phase 4	Anesthesia \| Pain, Procedural	57	Buprenorphine 0.15 MG (Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block)	yilywsdnqv(zvrvxevxtz) = iafzhcgwaz xcfzhogmnr (jlahnvepfc, qjnldbwkql - czkhkivniq) View more	-	01 Aug 2023
				Lidocaine 1% Injectable Solution (1% Lidocaine Paracervical Block)	yilywsdnqv(zvrvxevxtz) = bmqrkfmgld xcfzhogmnr (jlahnvepfc, rlggyapdak - alfpvqllcy) View more
NCT02651584 (FDA) Manual	Phase 3	Opioid-Related Disorders	428	BRIXADI	vrkzwwjvov(eripeeovri) = thnvpicwzd pupgmtnxny (mewxznqplv ) View more	Positive	23 May 2023
				buprenorphine/naloxone	vrkzwwjvov(eripeeovri) = qdwdrnvein pupgmtnxny (mewxznqplv ) View more
NCT02611752 (FDA) Manual	Phase 2	Opioid-Related Disorders	47	BRIXADI	kunifzapnh(nwejbvvrtf) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo gukqelaagf (dxhbekvgtn )	Positive	23 May 2023
				Placebo
NCT02187198 (CTgov)	Phase 3	Opium Dependence	9	Buprenorphine (Buprenorphine Low Dose)	ceapmsygwe(jylqkivbtw) = qdbnnkmodu zyjlubokcy (gsziqvvkzi, fpnyucqhnk - ogjludihqy) View more	-	10 Mar 2023
				Buprenorphine (Buprenorphine High Dose)	ceapmsygwe(jylqkivbtw) = xknbczajmv zyjlubokcy (gsziqvvkzi, vxbqnivhtz - jlvtbqevcd) View more
NCT02543944 (GBN, CTgov)	Phase 2/3	Unspecified drug dependence	117	Naltrexone (depot)+Buprenorphine+Clonidine+Gabapentin+Naltrexone (oral) (Gabapentin)	twpbxdbaup(nwkfrcnnkj) = lsovxrblui znguhwljiq (liuikhyjjb, mdsyljpyne - gpbpwkapky) View more	-	28 Jul 2022
				Placebo+Naltrexone (depot)+Buprenorphine+Clonidine+Naltrexone (oral) (Placebo)	twpbxdbaup(nwkfrcnnkj) = xntiqngugc znguhwljiq (liuikhyjjb, lorrjwxesr - lmlmmhbeyi) View more
NCT03232346 (CTgov)	Phase 3	Opioid-Related Disorders	11	Vivitrol (Regimen 1)	lkbidvezcy(dtpwxnrfzg) = mapnxncrjg kdqgebtnjt (swtgikzrib, pdofiazybv - nhvkqfhucm) View more	-	21 Jun 2022
				Buprenorphine (Regimen 2)	lkbidvezcy(dtpwxnrfzg) = fqofbnismw kdqgebtnjt (swtgikzrib, vcqgcnywet - xeptsbqfgs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis